Merck Enters Obesity Space, Buys Rights to Hansoh's Oral GLP-1 Drug [Yahoo! Finance]
Merck & Company, Inc. (new) (MRK)
Last merck & company, inc. (new) earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.merck.com/home/default.aspx
Company Research
Source: Yahoo! Finance
To foray into the lucrative obesity market, Merck MRK announced that it is in-licensing global rights to an investigational oral GLP-1 receptor agonist, HS-10535, from Chinese biotech Hansoh Pharma. For the exclusive global rights to develop, manufacture and commercialize this pre-clinical candidate, Merck will make an upfront payment of $112 million to Hansoh Pharma, with the latter also being entitled to receive up to $1.9 billion in milestone payments and royalties on sales. Hansoh has an option to co-promote or solely commercialize HS-10535 in China. For the deal, Merck will record a pre-tax charge of $112 million or 4 cents per share in the fourth quarter of 2024. The GLP-1 segment is a very important class of drugs for multiple cardiometabolic diseases like diabetes and obesity and is gaining significant popularity. GLP-1 drugs work by mimicking the hormone GLP-1, resulting in weight loss, lowering hemoglobin A1c (HbA1c) and reducing cardiovascular risks. Eli Lilly LLY
Show less
Read more
Impact Snapshot
Event Time:
MRK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRK alerts
High impacting Merck & Company, Inc. (new) news events
Weekly update
A roundup of the hottest topics
MRK
News
- Merck to Participate in the 43rd Annual J.P. Morgan Healthcare ConferenceBusiness Wire
- Merck & Co., Inc. (NYSE:MRK) is a favorite amongst institutional investors who own 79% [Yahoo! Finance]Yahoo! Finance
- Merck (MRK) Sees a More Significant Dip Than Broader Market: Some Facts to Know [Yahoo! Finance]Yahoo! Finance
- U.S. FDA approves injectable version of cancer drug from Bristol Myers Squibb [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- Will Weakness in Merck & Co., Inc.'s (NYSE:MRK) Stock Prove Temporary Given Strong Fundamentals? [Yahoo! Finance]Yahoo! Finance
MRK
Earnings
- 10/31/24 - Beat
MRK
Sec Filings
- 1/3/25 - Form 4
- 1/3/25 - Form 4
- 1/3/25 - Form 4
- MRK's page on the SEC website